Biotech News
Related news
KYMRKymera2026-06-12 11:00 EST
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
FATEFate Therapeutics2026-08-14 11:00 EST
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
RVMDRevolution Medicines2026-07-02 12:00 EST
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
NRIXNurix Therapeutics2026-08-04 11:00 EST
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
NRIXNurix Therapeutics2026-08-04 05:00 EST
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
KYMRKymera2026-06-25 11:00 EST
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
RVMDRevolution Medicines2026-06-23 12:00 EST
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
MGNXMacroGenics2026-07-23 20:01 EST
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
COGTCogent Biosciences2026-06-12 12:00 EST
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Y-mAbs
Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.
Recent company news
YMABY-mAbs2025-09-16 12:41 EST
SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics
YMABY-mAbs2025-08-08 10:35 EST
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
YMABY-mAbs2025-08-07 11:30 EST
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
YMABY-mAbs2025-08-05 12:30 EST
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
YMABY-mAbs2025-05-28 10:35 EST
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States